Clinical trial NCT01239979: Plasma Myeloperoxidase Levels in Patients With Coronary Artery Disease
Official title: Evaluation of the Association Between Myeloperoxidase Levels and Cardiovascular Risk Factors in Patients With Coronary Artery Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: coronary artery disease
Lead sponsor: Isfahan University of Medical Sciences
Sponsor class: OTHER
First posted: 2010-11-15
Enrollment: 150
Sex: ALL
Minimum age (years): 35
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: All subjects are diagnosed angiographically following chest pain, clinical manifestations or suspected changes on ECG at Isfahan Cardiovascular Research Center in Iran

Brief summary: The investigators sought to assess whether plasma myeloperoxidase (MPO) levels differ among patients with stable and unstable CAD patients and control subjects, and correlate with inflammatory and clinical risk factors such as ox-LDL, NO,leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine in the patients.

Detailed description: Elevation of the leukocyte enzyme myeloperoxidase (MPO) in stable coronary artery disease (CAD) patients in contrast to unstable CAD patients is controversial and its relationship with some inflammatory and noninflammatory markers such as oxidized LDL (ox-LDL) and nitric oxide (NO) in the CAD patients has not been evaluated yet. Evaluation of these relationships is the aim of the study.Also the relationships between MPO and some other inflammatory biomarker such as leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine are examined. This study includes 50 stable CAD, 50 unstable CAD patients and 50 controls. Plasma MPO, ox-LDL, leptin, adiponectin, sPLA2 levels are determined using enzyme immunoassay.Homocysteine and 3-nitrotyrosine are measured using HPLC-fluorescence method. Plasma total NO and other risk factors such as lipid profile, hypertension, smoking, diabetes mellitus and familial history of CAD are also determined in the patients. Results are statistically analysed and the association between all markers are assessed.

Eligibility criteria: Inclusion Criteria:

* Stable and unstable patients with angiographically documented coronary artery disease.
* Control subjects without angiographically documented coronary artery disease.

All subjects Exclusion Criteria:

* Patients with recent (with in 6 month) myocardial infarction or cardiovascular events,
* surgery (with in 3 month),
* cancer and
* infective or inflammatory diseases were not included in the study.

Primary outcomes:
measure: Plasma myeloperoxidase levels
timeFrame: 3 month
Secondary outcomes:
measure: Clinical risk factors
timeFrame: 3 month
Other outcomes:
Locations:
city: Isfahan
country: Iran, Islamic Republic of
facility: Isfahan Cardiovascular Research Center
Study officials:
affiliation: - Clinical Biochemistry Department, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
name: Saedzaaldin Samsamshariat, PhD
role: STUDY_DIRECTOR
References: